WHO: Study finds 4 drugs have little to no effect on mortality in severe COVID-19 cases

new warnings tonight that this pandemic is taking a devastating toll on rural America, Tennessee's health commissioner sounding an alarm for her state that has been very startling to me and the team over the last several days. Our death rate in rural population is double that in the urban population. In Kentucky, one of the least seven states that have just reported record high hospitalizations for one day, the governor says residents need to be jolted into action. Everybody ought to be concerned, and everybody ought to be doing the right thing and those that are out there that try to confront you for wearing a mask or being a jerk, that's all they are, and they're putting your health at risk. Wisconsin just reported more than 1000 hospitalizations, its highest number for a single day since the pandemic began. What's behind the spikes in rural areas across the U. S. Some of the bigger mandates that happen in cities like mask wearing and physical distancing are not really translating, are going as far as rural areas and concerns tonight about other states with large rural populations getting hit harder. In Georgia, the governor's executive orders requiring social distancing and limiting mass gatherings expire at midnight tonight and so far haven't been extended. This comes as 35 states are trending upward in experiencing new coronavirus cases. And for the first time in months, the U. S recorded nearly 60,000 new cases in one day on Wednesday. A lot of reasons that can explain these trends on number one. Fall weather usually brings colder temperatures, and that means more people are doing indoor activities, which is very high risk when it comes to virus transmission. Um, we're seeing some restrictions loosening in several states. Meantime, America's top voice on the pandemic, citing the dangers of household gatherings, told ABC that this year, MAWR Americans may have to forego bringing their extended families together for Thanksgiving. We really have to be careful this time, and each individual family evaluate the risk benefit of doing that. And there's new push back to the idea of so called herd immunity, letting the virus run unchecked through communities so more people would contract Cove in 19 the thought being some could later develop resistance to the virus. It's been promoted by some scientists and some people in the Trump administration, but 14 public health organizations are condemning the idea. If you just let things rip and let the infection go, no masks crowd. It doesn't make any difference that, quite frankly, is ridiculous.

The world's largest randomized trial of COVID-19 treatments found “conclusive evidence” that remdesivir, a drug used to treat U.S. President Donald Trump when he fell ill, has little or no effect on severe cases, the U.N. health agency said Friday.The World Health Organization announced the long-awaited results of a six-month trial that endeavored to see if existing drugs might have an effect on the coronavirus.The study, which was not peer-reviewed, found that four treatments tested — remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon — had “ little or no effect" on whether or not patients died within about a month or whether hospitalized patients recovered.Most of those had already been ruled out. But remdesivir, an antiviral, has been classified as standard-of-care in the United States, and it has been approved for use against COVID-19 in the UK and EU. Supplies of the drug have been limited, and the European Medicines Agency is now reviewing whether remdesivir is causing kidney problems as reported by some patients.The results of the global trial are in sharp contrast to a large study in the United States, which found remdesivir shortened the time to recovery by about five days on average.Martin Landray, a professor of medicine and epidemiology at Oxford University, said the WHO trial results for hydroxychloroquine and lopinavir were in line with a previous British study he co-led.“The big story is the finding that remdesivir produces no meaningful impact on survival,” he said in a statement. He said the drug is now recommended in some countries but there have been significant concerns about supply, cost and access.“This is a drug that has to be given by intravenous infusion for five to 10 days,” noting it costs about $2,550 per treatment course. “COVID affects millions of people and their families around the world. We need scalable, affordable, and equitable treatments."The treatments given to President Trump after he tested positive for the coronavirus included remdesivir.WHO said the study, which covered more than 30 countries, looked at the effects of the treatments on overall death rates, whether or not patients need breathing machines, and how much time patients spent recovering in hospitals.

GENEVA —

The World Health Organization announced the long-awaited results of a six-month trial that endeavored to see if existing drugs might have an effect on the coronavirus.

The study, which was not peer-reviewed, found that four treatments tested — remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon — had “ little or no effect" on whether or not patients died within about a month or whether hospitalized patients recovered.

Most of those had already been ruled out. But remdesivir, an antiviral, has been classified as standard-of-care in the United States, and it has been approved for use against COVID-19 in the UK and EU. Supplies of the drug have been limited, and the European Medicines Agency is now reviewing whether remdesivir is causing kidney problems as reported by some patients.

The results of the global trial are in sharp contrast to a large study in the United States, which found remdesivir shortened the time to recovery by about five days on average.

Martin Landray, a professor of medicine and epidemiology at Oxford University, said the WHO trial results for hydroxychloroquine and lopinavir were in line with a previous British study he co-led.

“The big story is the finding that remdesivir produces no meaningful impact on survival,” he said in a statement. He said the drug is now recommended in some countries but there have been significant concerns about supply, cost and access.

“This is a drug that has to be given by intravenous infusion for five to 10 days,” noting it costs about $2,550 per treatment course. “COVID affects millions of people and their families around the world. We need scalable, affordable, and equitable treatments."

The treatments given to President Trump after he tested positive for the coronavirus included remdesivir.

WHO said the study, which covered more than 30 countries, looked at the effects of the treatments on overall death rates, whether or not patients need breathing machines, and how much time patients spent recovering in hospitals.

��vlog